Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.001.41%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -60.48% | -44.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -60.48% | -44.99% | |||
| Operating Income | 60.48% | 44.99% | |||
| Income Before Tax | 63.53% | 54.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 63.53% | 54.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 63.53% | -116.98% | |||
| EBIT | 60.48% | 44.99% | |||
| EBITDA | 211.81% | 74.12% | |||
| EPS Basic | 256.04% | 97.88% | |||
| Normalized Basic EPS | 63.24% | 72.36% | |||
| EPS Diluted | 256.04% | 97.88% | |||
| Normalized Diluted EPS | 63.24% | 72.36% | |||
| Average Basic Shares Outstanding | 0.37% | 63.12% | |||
| Average Diluted Shares Outstanding | 0.37% | 63.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||